[go: up one dir, main page]

BR0317834A - Pyrimidin-4,6-dicarboxylic acid diacids as selective 13 mmp inhibitors - Google Patents

Pyrimidin-4,6-dicarboxylic acid diacids as selective 13 mmp inhibitors

Info

Publication number
BR0317834A
BR0317834A BR0317834-0A BR0317834A BR0317834A BR 0317834 A BR0317834 A BR 0317834A BR 0317834 A BR0317834 A BR 0317834A BR 0317834 A BR0317834 A BR 0317834A
Authority
BR
Brazil
Prior art keywords
pyrimidin
selective
dicarboxylic acid
mmp inhibitors
mmp
Prior art date
Application number
BR0317834-0A
Other languages
Portuguese (pt)
Inventor
Otmar Klingler
Reinhard Kirsch
Joerg Habermann
Klaus-Ulrich Weithmann
Christian Engel
Bernard Pirard
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR0317834A publication Critical patent/BR0317834A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DIAMIDAS DE áCIDO PIRIMIDIN-4,6-DICARBOXìLICO COMO INIBIDORES MMP 13 SELETIVOS". A presente invenção refere-se à aplicação da fórmula (I) na qual R1-R7 têm os significados indicados nas reivindicações, bem como sua aplicação para a inibição seletiva da colagenase (MMP 13). As diamidas de ácido pirimidin-4,6-dicarboxílico podem ser aplicadas, por conseguinte, para o tratamento de doenças articulares degenerativas."PYRIMIDIN-4,6-DICARBOXYLIC ACID DIAMIDES AS SELECTIVE MMP 13 INHIBITORS". The present invention relates to the application of formula (I) wherein R1-R7 have the meanings indicated in the claims as well as its application to selective collagenase inhibition (MMP 13). Pyrimidin-4,6-dicarboxylic acid diamides may therefore be applied for the treatment of degenerative joint diseases.

BR0317834-0A 2003-01-03 2003-12-19 Pyrimidin-4,6-dicarboxylic acid diacids as selective 13 mmp inhibitors BR0317834A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10300017A DE10300017A1 (en) 2003-01-03 2003-01-03 Selective MMP 13 inhibitors
PCT/EP2003/014612 WO2004060883A1 (en) 2003-01-03 2003-12-19 Pyrimidine-4,6-dicarboxylic acid diamides for use as selective mmp 13 inhibitors

Publications (1)

Publication Number Publication Date
BR0317834A true BR0317834A (en) 2005-11-29

Family

ID=32519591

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317834-0A BR0317834A (en) 2003-01-03 2003-12-19 Pyrimidin-4,6-dicarboxylic acid diacids as selective 13 mmp inhibitors

Country Status (11)

Country Link
EP (1) EP1587803A1 (en)
JP (1) JP2006515595A (en)
AR (1) AR042687A1 (en)
AU (1) AU2003293951A1 (en)
BR (1) BR0317834A (en)
CA (1) CA2512183A1 (en)
DE (1) DE10300017A1 (en)
MX (1) MXPA05006401A (en)
PE (1) PE20040916A1 (en)
TW (1) TW200505906A (en)
WO (1) WO2004060883A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060173183A1 (en) * 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
US20070155738A1 (en) * 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
US20070155737A1 (en) * 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
AU2006332694A1 (en) * 2005-12-30 2007-07-12 Alantos Pharmaceuticals, Holding, Inc. Substituted bis-amide metalloprotease inhibitors
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
AU2007321922A1 (en) * 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic matrix metalloprotease inhibitors
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
US9035072B2 (en) 2010-04-22 2015-05-19 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
PT3925607T (en) 2014-04-15 2023-09-26 Vertex Pharma Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
GB201908453D0 (en) * 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931432A1 (en) * 1989-09-21 1991-04-04 Hoechst Ag PYRIMIDIN-4,6-DICARBONSAEUREDIAMIDE, METHOD FOR THE PRODUCTION AND USE THEREOF AND MEDICINAL PRODUCTS BASED ON THESE COMPOUNDS
WO2002064571A1 (en) * 2001-02-14 2002-08-22 Warner-Lambert Company Llc Pyrimidine matrix metalloproteinase inhibitors
DE10160357A1 (en) * 2001-12-08 2003-06-18 Aventis Pharma Gmbh Use of pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides for the selective inhibition of collagenases

Also Published As

Publication number Publication date
EP1587803A1 (en) 2005-10-26
AR042687A1 (en) 2005-06-29
WO2004060883A1 (en) 2004-07-22
PE20040916A1 (en) 2005-01-25
MXPA05006401A (en) 2005-08-19
AU2003293951A1 (en) 2004-07-29
TW200505906A (en) 2005-02-16
CA2512183A1 (en) 2004-07-22
JP2006515595A (en) 2006-06-01
DE10300017A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
BR0209774A (en) Cdk inhibitor pyrimidines, their preparation and application as a medicament
BR0316680A (en) Chk, pdk and akt inhibitor pyrimidines, their production and use as pharmaceutical agents
BR0307564A (en) Nicotinamide derivatives useful as pde4 inhibitors
BR0309556A (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
BRPI0516842A (en) compounds, process for their manufacture, pharmaceutical compositions comprising them, method for the therapeutic and / or prophylactic treatment of diseases that are modulated by lxr alpha and / or lxr beta agonists and use of such compounds
BR0317872A (en) Anti-Inflammatory Drugs
BR9810920A (en) Modification of the crystal form of a derivative of n-phenyl-2-pyrimidinoamine, processes for its manufacture and use
BRPI0409109A (en) new compounds
BR0015026A (en) Indoles replaced for the modulation of nfkb activity
BR0314379A (en) Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
BRPI0515931A (en) compounds, process for their preparation, pharmaceutical compositions comprising them, method for treating and / or prophylaxis of diseases and use of such compounds
BRPI0407454A (en) Pyrazoles and methods of preparing and using them
BR0314393A (en) Heterocyclic Substituted Piperazines for the Treatment of Schizophrenia
BR0314071A (en) 1,3-Diamino-2-hydroxypropane prodrug derivatives
BR0207883A (en) Anticholenergic and pde-iv inhibitor drug compositions
BR0209957A (en) Compound, process for preparing a compound, pharmaceutical composition comprising a compound, use of such compound and process for the treatment and prophylaxis of arthritis, diabetes, eating disorders and obesity
BR0112538A (en) Stable salts of o-acetylsalicylic acid with basic amino acids
BR0016195A (en) 4-pyrimidinyl-n-acyl-1-phenylalanines
PA8559401A1 (en) SUCCINIC ACID SALTS OF 5,7,14-TRIAZATETRACICLO (10.3.1.0 2,11.0 4, 9) -HEXADECA-2 (11), 3,5,7,9-PENTAENO AND PHARMACEUTICAL COMPOSITIONS OF THE SAME.
CR8926A (en) TIAZOLO-NAFTILO ACIDS
BR0206501A (en) Cruzipain and other cysteine protease inhibitors
BR0307574A (en) Nicotinamide derivatives useful as pde4 inhibitors
BR0317834A (en) Pyrimidin-4,6-dicarboxylic acid diacids as selective 13 mmp inhibitors
HN2003000038A (en) ESTERES HYDROXAMATE ACID N- (4-PHENYL-REPLACED) -ANTRANILICO
BRPI0415203A (en) restructured pentanols, a process for their production and use as anti-inflammatory agents

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A ANUIDADE

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.